summari host investor meet manag
overal believ compani well posit
achiev long-rang plan lrp despit
uncertainti outlook bax outlook driven
combin innov compani develop
pipelin busi develop solid oper execut
key take-away meet follow organ pipelin
busi develop propel long-term growth inject
pharmaceut organ pipelin remain key driver
innov rest busi manag remain
confid achiev financi target despit reset
sale guidanc capit alloc strategi unchang
 possibl year ahead rais price target
base blend ev/ebitda pe/g dcf
grow
via busi develop bd compani
organ via bd first manag acknowledg need
broaden product portfolio becom competit
mean need add gener molecul
offer develop intern via recent deal like
clari scinopharm second plan reformul
molecul ready-to-us product better facilit
hospit need final plan evalu biosimilar
opportun leverag exist manufactur capabl
commerci process howev manag note
take time develop obtain regulatori approv
product formul may analyst day note
current pharmaceut busi target market
see potenti doubl address market
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust spin-off baxalta
compani data secur llc estim reuter
continu previou page
organ pipelin track rest busi infus system remain track
develop new pump platform includ lvp larg volum parenter syring
pca patient-control analges compani aim introduc integr platform
facilit workflow across pump format work model lvp syring pump
develop pca modul on-going continu target launch us
plan roll global time crrt continu renal replac therapi prismax launch
europ go well regulatori review us underway compani plan
develop version prismax emerg market pd periton dialysi clinic trial
new poc point care system expect enrol first patient year-end compani
remain track us launch plan evalu ou opportun base afford
reimburs nutrit focus intern develop product neonat
oncolog segment advanc surgeri manag highlight floseal hemostat platform
focus formul ready-to-us version readi use within minut
manag confid lrp despit shortfal bax financi target set may
analyst meet remain intact lower sale base anticip
sale compound-annual-growth-rate ep sale compound-annual-growth-rate ep
manag note lrp project reflect organ growth momentum
innov like new pump platform result disappoint manag firmli
believ issu short-term challeng structur issu believ manag
sound even confid longer term ep outlook especi compani abl
reiter call essenti high-end ep guidanc rang despit top-lin
shortfal said lower base continu see busi develop
share repurchas potenti play greater role achiev longer term target forecast
sale compound-annual-growth-rate ep sale compound-annual-growth-rate ep
continu see recoveri iv solut nutrit guid
oper sale growth ex-fx cyclo adjust easi comp hurrican
maria last year growth closer midpoint rang manag
expect recoveri medic deliv nutrit process like take sever quarter
probabl slip lvp larg volum parenter work gpo group purchas
organ secur long-term contract provid framework price sign deal
larg gpo svp small volum parenter expect recaptur much share
lost iv push competitor expect process last similarli nutrit
work american societi nutrit re-establish treatment guidelin educ
member best practic expect measur recoveri come quarter
await call outlook consist prior discuss manag declin talk
outlook next year give full guidanc call compani note
number put take consid includ cyclo brevibloc competit tough
comp iv solut surprisingli compani expect continu margin expans
current forecast sale oper growth ep
capit alloc strategi intact potenti go forward repurchas
share recent exist stock buy-back program compani continu assess
intrins valu stock price market price make opportunist purchas
team strategi place manag hope put balanc sheet work
year compar last year howev expect remain disciplin deal assess
includ top-lin growth synergi bax current leverag ratio remain well
industri averag assum net debt/ebitda leverag estim borrow
would provid signific financi flexibl and/or share repurchas
price target
price target base equal weight ev/ebtida dcf p/e/g risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ re-acceler sale growth continu expand oper margin resum
low double-digit ep growth strong balanc sheet could enhanc long-term growth outlook
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
